Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
(Thomson Reuters ONE) -
Oslo, Norway, 8 May 2017 - Targovax ASA ("Targovax" or "the Company"; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target solid tumors, will be hosting Capital Markets Updates in Oslo on
Thursday 8 June and in London on Monday 26 June 2017.
The meetings, which will be open to analysts, brokers, investors and press, will
include presentations from world leading experts on resected pancreatic cancer
patients, as well as from Targovax's senior management team. Presentations are
expected to cover the following areas:
* Introduction to Targovax
* Technology and clinical trials
* A clinician's view on pancreatic cancer and current treatment options
* Overview of TG01 data from the Phase I/II resected pancreatic cancer trial
presented at ASCO, presented by one of the principal investigators
A formal program will be announced nearer the time.
To register for the Oslo event, please contact renate.birkeli(at)targovax.com.
To register for the London event, please contact
hanna.skeppner(at)fticonsulting.com.
###
For further information, please contact
Renate Birkeli, IR
Phone: +47 922 61 624
Email: renate.birkeli(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)fticonsulting.com
About Targovax
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be an immune activator that selectively target cancer cells. In
phase I it has shown to immune activate at lesional level which was associated
with clinical benefit. We expect proof of concept data for this platform in
2017 from a clinical trial of lead product ONCOS-102 in patients with refractory
malignant melanoma.
The second platform, TG peptides (TG), solely targets tumors that express
mutated forms of the RAS protein. Mutations to this protein are common in many
cancers and are known to drive aggressive disease progression and treatment
resistance. There is a high unmet medical need for therapies that are effective
against tumors that express these mutations. The TG platform's therapeutic
potential stems from its ability to enable a patient's immune system to identify
and then destroy tumors bearing any RAS mutations. In early 2017, key proof of
concept data for the TG platform from a clinical trial of TG01 in resected
pancreatic cancer patients showed encouraging overall survival and will give
guidance for the future clinical development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in
clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, we have other products in early stages of development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the
shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2017 - 07:01 Uhr
Sprache: Deutsch
News-ID 540721
Anzahl Zeichen: 4673
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 346 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
